Brokerages forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will report ($0.19) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for AzurRx BioPharma’s earnings, with estimates ranging from ($0.20) to ($0.17). The business is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.84) to ($0.80). For the next year, analysts expect that the company will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.74) to ($0.49). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for AzurRx BioPharma.
A number of brokerages have recently issued reports on AZRX. CIBC began coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 price target on the stock. Oppenheimer initiated coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 price target on the stock. HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research report on Tuesday, October 16th. ValuEngine upgraded AzurRx BioPharma from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Roth Capital initiated coverage on AzurRx BioPharma in a research report on Friday, January 25th. They set a “buy” rating and a $10.50 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $7.63.
An institutional investor recently raised its position in AzurRx BioPharma stock. Vanguard Group Inc raised its holdings in AzurRx BioPharma Inc (NASDAQ:AZRX) by 2.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 413,439 shares of the company’s stock after purchasing an additional 8,489 shares during the quarter. Vanguard Group Inc owned 2.44% of AzurRx BioPharma worth $1,063,000 as of its most recent SEC filing. 18.98% of the stock is owned by institutional investors.
Shares of NASDAQ:AZRX opened at $1.88 on Monday. AzurRx BioPharma has a 1 year low of $1.00 and a 1 year high of $3.75.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
See Also: Coverage Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.